Nov 1 (Reuters) - The U.S. Medicare federal health insurance program has confirmed plans to remove a requirement that kidney dialysis providers keep patient hemoglobin levels above a set minimum -- a move likely to reduce use of Epogen, the anemia drug sold by Amgen Inc .
In a statement on its website on Tuesday, the agency issued a final rule to remove, starting in payment year 2013, a requirement that patients' hemoglobin, or red blood cell, levels be kept above 10 milligrams per deciliter.
It said the action was consistent with labeling approved by the FDA (Food and Drug Administration).
Wednesday, November 02, 2011
U.S. Medicare confirms changes in anemia drug use | Reuters